Purpose. The results of a study to assess the effectiveness and safety of hyperglycemia management provided by clinical pharmacy specialists (CPSs) versus usual care in outpatients with diabetes from 53 Veterans Affairs (VA) medical centers are reported.
D
iabetes mellitus affects 30.3 million individuals in the United States, or 9.4% of the population. 1 In calendar years 2003-06, death rates from cardiovascular disease were approximately 1.7 times higher for adults with diabetes than for those without diabetes. 2 In addition to cardiovascular disease, patients with diabetes have increased risks of nephropathy, skin infections, neuropathy, and eye problems, among other conditions. 3 Diabetes is one of the most prevalent disease states among veterans in the Veterans Health Administration (VHA); nearly 1 in 4 veterans receiving care from VHA has diabetes. Veterans are at increased risk for type 2 diabetes, which is partially attributable to their older age, the high proportion who are obese or overweight (~70%), and the association between diabetes and exposure to herbicides, such as Agent Orange. 4 The increased prevalence of diabetes among veterans, together with the increased comorbidity associated with the disease, can lead to a greater demand for healthcare services. 5 In addition, given the emphasis on glucose control in an effort to decrease the complications associated with diabetes, more contact with healthcare providers is often needed to manage dysglycemia. Demand for physicians continues to outpace supply, with a shortfall ranging between 40,800 and 104,900 projected by 2030. When looking just at primary care physicians, the forecasted shortfall is between 7,300 and 43,100. 6 In order to improve access to physicians for the diagnosis and treatment of diabetesrelated complications and other comorbidities, the clinical pharmacy specialist (CPS) can help with therapeutic management of patients with uncontrolled glucose levels. Within VHA, the CPS is an advanced practice provider with a scope of practice that includes medication prescribing and authority to provide comprehensive medication management services across a spectrum of common disease states, including diabetes.
A recent review examined the effectiveness and harms associated with chronic disease management performed by pharmacists. 7 This review concluded that the care provided by pharmacists was similar to usual care in the area of resource utilization and that pharmacist care was associated with improvement in attaining physiological goals. Other studies have demonstrated positive outcomes associated with pharmacist-managed care for diabetes; however, they often lacked control groups, had small numbers of patients, or were conducted in a limited number of care settings. [8] [9] [10] [11] [12] The goal of the study described here was to assess the effectiveness and safety of hyperglycemia management provided by CPSs versus usual care in outpatients with diabetes from 53 Veterans Affairs (VA) medical centers.
Methods
A historical cohort study was conducted to evaluate clinical outcomes in diabetic patients with a baseline glycosylated hemoglobin (HbA1 c ) concentration of >9% in 2012 who were referred to CPSs for management of hyperglycemia (the pharmacist-managed group) versus outpatients in primary care who were not referred to a CPS (the usual care group) during the study period. Patients were included if they had 2 or more outpatient visits in the 12 months preceding the HbA1 c value of >9% and an outpatient prescription for a nonantidiabetic medication; the latter inclusion criterion served to limit the cohort to patients whose primary care was likely managed by a VA provider. The index visit with the CPS was the first visit after the referral, which was identified by the presence of a clinical reminder "health factor. " A health factor is an embedded discrete data element with standardized nomenclature that allows for easy data retrieval within a VA central database. The index visit in usual care was the primary care visit that followed the first HbA1 c value of >9% in 2012; this could occur on the same day as the HbA1 c result. Patients were followed for 18 months after the index date plus 45 days. Data from the electronic health record is available within VHA's Corporate Data Warehouse (CDW), and the standardized health factors nomenclature structure allows for easy data retrieval within this database.
Outcome measures. The primary outcome measures were the change in HbA1 c over time and the time to reach an HbA1 c values of <8% and <9% in each treatment group. The secondary outcome measures were the mean number of patient visits to achieve HbA1 c values of <8% and <9% and several safety measures. The latter included (1) the proportion of patients with an HbA1 c of <7% in each treatment group who were receiving insulin or secretagogues and were 75 years of age or older, had a serum creatinine concentration of ≥2.0 mg/dL, or had a diagnosis of cognitive impairment or dementia, (2) In determining whether the HbA1 c concentration was measured while patient was on insulin or secretagogues, we assumed that treatment started on the medication's release date and extended for the number of days supplied by the prescription plus an additional 60 days.
Statistical analysis. Propensity score matching was performed to adjust for potential treatment selection bias. 13 In our analysis, a propensity score was obtained from a logistic regression model using baseline patient-level covariates related to demographics, vital signs, laboratory test results, comorbid conditions, and use of medications for mental health conditions. Pairs of patients in the pharmacist-managed and usual care groups were matched 1:1 using a greedy matching technique with a caliper width of 0.2 S.D. of the logodds ratio of the calculated propensity scores.
14 Balancing of the covariates in the matched data set was examined by
KEY POINTS
• The study results presented here provide additional support for the use of clinical pharmacy specialists (CPSs) in medication management to increase patient access to primary care physicians.
• CPSs can be a key resource for improved medication management in patients with diabetes that has a positive impact on glucose control and reduces overall healthcare system costs.
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standardized differences, with a difference of less than 10% considered to indicate good balance. 15 The effect of the 2 treatment groups on HbA1 c was estimated using a mixedeffects regression model. There were no prespecified scheduled clinic visits for the assessment of HbA1 c . As such, longitudinal data in 30-day intervals from the index visit of each patient were created for the mixed-effects regression analysis.
Comparisons of time-to-event distributions (i.e., the time to reach HbA1 c values of <8% and <9%) were made using the Kaplan-Meier method, and the differences in survival curves were examined using the log-rank test. Risk ratios were estimated using Cox proportional hazard models. The proportional hazard assumption was examined by testing the treatment-time interaction term.
For the secondary outcome measures, descriptive data analyses were performed to calculate mean, S.D., frequency, and percentage values. Potential group differences in secondary outcome measures were examined via t tests and via chi-square and/or Fisher's exact test as appropriate. All data analyses were performed using SAS, version 9.2 software for Windows (SAS Institute, Cary, NC). The study was approved by the institutional review board of Edward Hines, Jr. VA Hospital, Hines, Illinois, and James A. Lovell Federal Health Care Center, North Chicago, Illinois.
Results

Patient characteristics.
The study cohort prior to propensity score matching consisted of 12,407 patients in the pharmacist-managed group and 85,740 patients in the usual care group. At baseline, patients in the pharmacistmanaged group had a slightly higher mean HbA1 c value (10.5% versus 10.3%), a greater percentage with a body mass index (BMI) of ≥30 kg/m 2 (68% versus 61%), a higher proportion of African Americans (27% versus 22%), and higher proportions of patients who were receiving antidiabetic medications 12 months prior to the index date (90% versus 84%) and patients receiving insulin only (35% versus 29%). After propensity score matching, the 12,327 patients in the pharmacist-managed and usual care groups were well matched for baseline characteristics (Table 1) .
Glycemic control. The mean HbA1 c values over time were comparable in the pharmacist-managed and usual care groups (Figure 1 ). On average, both groups experienced the most HbA1 c lowering during the first 90 days after the index visit, and HbA1 c values remained fairly stable during the remainder of the study period. The average HbA1 c value was slightly lower (by 0.3%) in the usual care group versus the pharmacist-managed group at month 1 (p < 0.001), but no significant between-group differences were observed in months 2-18 ( Table 2) . When evaluating the time to reach HbA1 c values of <8% and <9% for each treatment group, patients in the pharmacist-managed group reached those endpoints faster than the usual care group (p < 0.001) (Figure 2) . At 180 days, 22% of the pharmacist-managed group had reached an HbA1c of <8%, as compared with 20% in the usual care group. At that same time point, 46% of patients in the pharmacist-managed group versus 38% in usual care had reached an HbA1 c value of <9%. The proportional hazards assumption was violated, so the hazard ratios (HRs) were estimated from the extended Cox regression model. The HR for attaining an HbA1 c value of <8% at 3 months was 1.05 (95% confidence interval [CI], 1.00-1.11); at 6 months, 1.15 (95% CI, 1.10-1.19); and at 12 months, 1.37 (955 CI, 1.30-1.45) with pharmacist-managed versus usual care. The HR for HbA1 c value of <9% at 3 months was 1.23 (95% CI, 1.18-1.27); at 6 months, 1.32 (95% CI, 1.28-1.36), and at 12 months, 1.54 (95% CI, 1.47-1.62).
Visits to achieve glycemic control. On average, the number of visits to achieve HbA1 c values of <8% and <9% were greater in the pharmacist-managed group. The mean ± S.D. numbers of visits to reach an HbA1 c value of <8% were 2.46 ± 1.58 and 1.82 ± 1.27 in the pharmacist-managed and usual care groups, respectively (p < 0.001). The mean ± S.D. numbers of visits to reach an HbA1 c value of <9% were 1.86 ± 1.30 for the pharmacist-managed group and 1.48 ± 1.01 for the usual care group (p < 0.001).
Safety outcomes. There were 2,091 patients with an HbA1 c value of <7% who were receiving insulin or secretagogues in the pharmacist-managed group and 1,753 such patient in the usual care group (p < 0.001). Of these patients, 21 .6% in the pharmacist-managed group and 21.5% in the usual care group had 1 or more of the evaluated risk factors for hypoglycemia, which included age of ≥75 years, a serum creatinine of ≥2 mg/dL, and a diagnosis of dementia (p = 0.97). There were 879 patients with an HbA1 c value of <6.5% and 316 patients with an HbA1 c value of <6.0% who were receiving insulin or secretagogues in the pharmacist-managed group and 838 and 317 such patients, respectively, in the usual care group (p < 0.001) ( Table 3) . Considering only patients who were taking a secretagogue only and had an HbA1 c value of <6.5%, there were 483 patients in the pharmacist-managed group and 522 in the usual care group (p = 0.65); among those with an HbA1 c value of <6.0%, there were 168 in the pharmacist-managed group and 190 in the usual care group (p = 0.73). Finally, serious hypoglycemia was noted in 4.3% of the pharmacist-managed patients and 3.1% of the usual care patients (p < 0.001).
Discussion
Our results indicate that CPSs managed the care of patients with hyperglycemia as well as non-CPS providers, as evidenced by the similar mean HbA1 c values over the study period. In addition, while there was no difference at 3 months, patients in the pharmacistmanaged group were 15% and 37% more likely to reach an HbA1 c value of <8% at 6 and 12 months, respectively. The results were similar for patients reaching an HbA1 c value of <9%. This finding was likely a result of patients being seen more frequently by the pharmacists. In addition to glucose control, we also evaluated several safety measures. Although there were more patients with HbA1 c values of <6.5% and <6% in the usual care versus the CPS-managed group, a higher percentage of these patients were receiving insulin in the pharmacist-managed group. The use of insulin and secretagogues in patients with low HbA1 c values is an indicator of overtreatment and places the patients at an increased risk for hypoglycemia. 16, 17 However, even though the patients were well matched on multiple characteristics, we do not know if those in the pharmacist-managed group had more severe or difficult-to-control disease that required the use of insulin to lower HbA1 c levels. In addition, we were unable to assess whether insulin doses were decreased after these results. Also, a higher proportion of patients in the pharmacist-managed group versus the usual care group experienced an episode of hypoglycemia, although the absolute difference of 1.2% was small.
Studies examining CPS provision of direct patient care to patients with diabetes in the outpatient setting are plentiful, and this practice has been shown to improve patient outcomes. [8] [9] [10] [11] [12] [18] [19] [20] [21] [22] [23] However, many of these studies had small numbers of patients, lacked control groups, or were conducted in a limited number of care settings. Similar to our study, a study by Jacobs et al. 24 compared a group having pharmacist visits and a group receiving usual care over 1 year and found no significant difference between the groups in the percentage of patients reaching an HbA1 c value of <7%. The number of patients in that study was small, however. A second study that retrospectively compared a pharmacistintervention group and a usual care group found that a larger proportion of patients in the pharmacist-managed group achieved HbA1 c values of <7% and <8%; however, the study adjusted for few potential confounders. 25 Our study was one of the first multisite studies comparing pharmacist-managed care with usual care in patients with hyperglycemia that included large numbers of patients and a robust statistical analysis to match the groups based on baseline patient-level covariates.
Despite these strengths, there were several limitations to our study. We were not able to account for other individuals, such as dietitians and social workers, who may have contributed to the diabetes care in either group, and it is unknown what effect, if any, this may have had on the results. In addition, patients in the pharmacist-managed group were not always followed by a CPS over the entire study period; they may have been discharged back to usual care. However, we wanted to look at how well glucose control was maintained over the 18-month time period in patients who were managed by a CPS and then went back to usual care. Patients in the usual care group were never treated by a CPS during the study period. Also, we most likely did not capture all hypoglycemic events, because patients typically go to the closest hospital for management of acute events, but this probably occurred to the same extent in both groups. Likewise, we suspect that we did not capture all HbA1 c values that were obtained, because patients may have had laboratory work done outside of the VA system, and these results do not always appear in the electronic health record; this was probably more common in the usual care group, because the CPSs were monitoring patients more frequently. However, we attempted to address these last 2 limitations by including only patients who were regular users of care within the VHA system.
Our findings provide additional support for the use of CPSs in medication management so that more physician time is available for patients who require access to physicians, which may help to alleviate the shortage of primary care physicians. Including CPSs as members of the interprofessional care team can free up physician time for diagnosis and treatment of complications of diabetes and other comorbidities. Working in an interprofessional model, CPSs can be a key resource for improved medication management in patients with diabetes and have a positive impact on glucose control and reduction of overall healthcare system costs.
Conclusion
Data from 53 VA medical centers revealed that CPSs managed the care of ambulatory care patients with hyperglycemia as well as primary care providers. Therapy started on prescription release date and extended for the number of days supplied by the prescription plus an additional 60 days.
